参考文献/References:
[1] Shi S,Tang Y,Zhao Q,et al. Prevalence and risk of atrial fibrillation in China:a national cross-sectional epidemiological study[J]. Lancet Reg Health West Pac,2022,23:100439
[2] Hajjar LA,Fonseca SMR,Machado TIV. Atrial fibrillation and cancer[J]. Front Cardiovasc Med,2021,8:590768.
[3] Fitzpatrick T,Carrier M,Le Gal G. Cancer,atrial fibrillation,and stroke[J]. Thromb Res,2017,155:101-105.
[4] Chu G,Versteeg HH,Verschoor AJ,et al. Atrial fibrillation and cancer—An unexplored field in cardiovascular oncology[J]. Blood Rev,2019,35:59-67.
[5] Vedovati MC,Giustozzi M,Verdecchia P,et al. Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study[J]. Int J Cardiol,2018,269:152-157.
[6] Chebbout R,Heywood EG,Drake TM,et al. A systematic review of the incidence of and risk factors for postoperative atrial fibrillation following general surgery[J]. Anaesthesia,2018,73(4):490-498.
[7] Farmakis D,Parissis J,Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer[J]. J Am Coll Cardiol,2014,63(10):945-953.
[8] Chen PS,Tan AY. Autonomic nerve activity and atrial fibrillation[J]. Heart Rhythm,2007,4(3 Suppl):S61-S64.
[9] Yalcin MU,Gurses KM,Kocyigit D,et al. Elevated M2-muscarinic and β1-adrenergic receptor autoantibody levels are associated with paroxysmal atrial fibrillation[J]. Clin Res Cardiol,2015,104(3):226-233.
[10] Yalcin MU,Gurses KM,Kocyigit D,et al. Cardiac autoantibody levels predict recurrence following cryoballoon-based pulmonary vein isolation in paroxysmal atrial fibrillation patients[J]. J Cardiovasc Electrophysiol,2015,26(6):615-621.
[11] Gurses KM,Yalcin MU,Kocyigit D,et al. M2-muscarinic acetylcholine receptor autoantibody levels predict left atrial fibrosis severity in paroxysmal lone atrial fibrillation patients undergoing cryoablation[J]. Europace,2015,17(2):239-246.
[12] Wickramasinghe SR,Patel VV. Local innervation and atrial fibrillation[J]. Circulation,2013,128(14):1566-1575.
[13] Dobrev D,Aguilar M,Heijman J,et al. Postoperative atrial fibrillation: mechanisms,manifestations and management[J]. Nat Rev Cardiol,2019,16(7):417-436.
[14] Bessissow A,Khan J,Devereaux PJ,et al. Postoperative atrial fibrillation in non-cardiac and cardiac surgery: an overview[J]. J Thromb Haemost,2015,13(Suppl 1):S304-S312.
[15] Bruins P,te Velthuis H,Yazdanbakhsh AP,et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia[J]. Circulation,1997,96(10):3542-3548.
[16] Hak ?,My?liwska J,Wieckiewicz J,et al. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG) [J] . J Interferon Cytokine Res,2009,29(6):327-332.
[17] Barnes WS. Depressing effects of calcium antagonists on oxygen consumption in isolated skeletal muscle during potassium depolarization[J]. Can J Physiol Pharmacol,1988,66(6):836-840.
[18] Stoppe C,Rex S,Goetzenich A,et al. Interaction of MIF family proteins in myocardial ischemia/reperfusion damage and their influence on clinical outcome of cardiac surgery patients[J]. Antioxid Redox Signal,2015,23(11):865-879.
[19] Hu YF,Chen YJ,Lin YJ,et al. Inflammation and the pathogenesis of atrial fibrillation[J]. Nat Rev Cardiol,2015,12(4):230-243.
[20] Heerdt PM,Kant R,Hu Z,et al. Transcriptomic analysis reveals atrial KCNE1 down-regulation following lung lobectomy[J]. J Mol Cell Cardiol,2012,53(3):350-353.
[21] Lohani KR,Nandipati KC,Rollins SE,et al. Transthoracic approach is associated with increased incidence of atrial fibrillation after esophageal resection[J]. Surg Endosc,2015,29(7):2039-2045.
[22] Ma JY,Wang Y,Zhao YF,et al. Atrial fibrillation after surgery for esophageal carcinoma: clinical and prognostic significance[J]. World J Gastroenterol,2006,12(3):449-452.
[23] Wu JH,Marchioli R,Silletta MG,et al. Oxidative stress biomarkers and incidence of postoperative atrial fibrillation in the omega-3 fatty acids for prevention of postoperative atrial fibrillation (OPERA) trial[J]. J Am Heart Assoc,2015,4(5):e001886.
[24] Sovari AA,Dudley SC. Antioxidant therapy for atrial fibrillation:lost in translation?[J]. Heart,2012,98(22):1615- 1616.
[25] Briones AM,Touyz RM. Oxidative stress and hypertension:current concepts[J]. Curr Hypertens Rep,2010,12(2):135-142.
[26] Grieve DJ,Shah AM. Oxidative stress in heart failure. More than just damage[J]. Eur Heart J,2003,24(24):2161-2163.
[27] Fukunaga N,Takahashi N,Hagiwara S,et al. Establishment of a model of atrial fibrillation associated with chronic kidney disease in rats and the role of oxidative stress[J]. Heart Rhythm,2012,9(12):2023-2031.
[28] Li Y,Sheng L,Li W,et al. Probucol attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in dogs[J]. Biochem Biophys Res Commun,2009,381(2):198-203.
[29] Wu JH,Lemaitre RN,King IB,et al. Association of plasma phospholipid long-chain ω-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study[J]. Circulation,2012,125(9):1084-1093.
[30] Leitinger N,Huber J,Rizza C,et al. The isoprostane 8-iso-PGF(2alpha) stimulates endothelial cells to bind monocytes:differences from thromboxane-mediated endothelial activation[J]. FASEB J,2001,15(7):1254-1256.
[31] Huber J,Bochkov VN,Binder BR,et al. The isoprostane 8-iso-PGE2 stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP kinase-dependent signaling pathways[J]. Antioxid Redox Signal,2003,5(2):163-169.
[32] Sardar P,Kundu A,Chatterjee S,et al. Transcatheter versus surgical aortic valve replacement in intermediate-risk patients:evidence from a meta-analysis[J]. Catheter Cardiovasc Interv,2017,90(3):504-515.
[33] Ai D,Lasala J,Mehran JR,et al. Preoperative echocardiographic parameters of diastolic dysfunction did not provide a predictive value for postoperative atrial fibrillation in lung and esophageal cancer surgery[J]. J Cardiothorac Vasc Anesth,2015,29(5):1127-1130.
[34] Amar D,Zhang H,Shi W,et al. Brain natriuretic peptide and risk of atrial fibrillation after thoracic surgery[J]. J Thorac Cardiovasc Surg,2012,144(5):1249-1253.
[35] Nojiri T,Maeda H,Takeuchi Y,et al. Predictive value of B-type natriuretic peptide for postoperative atrial fibrillation following pulmonary resection for lung cancer[J]. Eur J Cardiothorac Surg,2010,37(4):787-791.
[36] Gibson PH,Croal BL,Cuthbertson BH,et sl. Use of preoperative natriuretic peptides and echocardiographic parameters in predicting new-onset atrial fibrillation after coronary artery bypass grafting: a prospective comparative study[J]. Am Heart J,2009,158(2):244-251.
[37] Amar D,Burt ME,Bains MS,et al. Symptomatic tachydysrhythmias after esophagectomy:incidence and outcome measures[J]. Ann Thorac Surg,1996,61(5):1506-1509.
[38] Stephens DM,Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia[J].Blood,2019,133(12):1298-1307.
[39] Tuomi JM,Xenocostas A,Jones DL. Increased susceptibility for atrial and ventricular cardiac arrhythmias in mice treated with a single high dose of ibrutinib[J]. Can J Cardiol,2018,34(3):337-341.
[40] McMullen JR,Boey EJ,Ooi JY,et al. Ibrutinib increases the risk of atrial fibrillation,potentially through inhibition of cardiac PI3K-Akt signaling[J]. Blood,2014,124(25):3829-3830.
[41] Pretorius L,Du XJ,Woodcock EA,et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation[J]. Am J Pathol,2009,175(3):998-1009.
[42] Alexandre J,Moslehi JJ,Bersell KR,et al. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms[J]. Pharmacol Ther,2018,189:89-103.
[43] Qureshi WT,O’Neal WT,Khodneva Y,et al. Association between opioid use and atrial fibrillation: the reasons for geographic and racial differences in stroke (REGARDS) study[J]. JAMA Intern Med,2015,175(6):1058-1060.
[44] Lendeckel U,Müller C,R?cken C,et al. Expression of opioid receptor subtypes and their ligands in fibrillating human atria[J]. Pacing Clin Electrophysiol,2005,28(suppl 1):S275-S279.
[45] Al-Hasani R,Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior[J]. Anesthesiology,2011,115(6):1363-1381.
[46] Wang SY,Long JB,Hurria A,et al. Cardiovascular events,early discontinuation of trastuzumab, and their impact on survival[J]. Breast Cancer Res Treat,2014,146(2):411-419.
[47] Chen J,Long J,Hurria A,et al. Early termination of adjuvant trastuzumab associated with cardiovascular events in older women with breast cancer[J]. Circulation,2012,126(21): A18979.
[48] Lampson BL,Yu L,Glynn RJ,et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib[J]. Blood,2017,129(18):2581-2584.
[49] ElZarrad MK,Mukhopadhyay P,Mohan N,et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice[J]. PLoS One,2013,8(11):e79543.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(10):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(10):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(10):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(10):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(10):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]